Guggenheim reiterates Merck stock rating ahead of Q3 earnings
Guggenheim maintained a Buy rating and $170 price target for Merck (NYSE:MRK) ahead of Q3 2026 earnings. The firm adjusted estimates, lowering Q3 sales to $17.44B and EPS to $2.08, citing R&D charges. Full-year estimates were also reduced. Merck's earnings call may focus on pipeline progress and recent data releases. The company faces a patent infringement ruling in Europe and has entered a licensing agreement for an oral KRASG12D inhibitor.
How this was made
The 30-second read
Why it matters
The downgrade in sales and EPS forecasts could pressure MRK shares ahead of the earnings call, though the Buy rating may cushion the move.
Market read
Analyst rating and forecast changes are a primary catalyst for MRK ahead of its earnings, offering a short‑term trading signal.
What to watch
Potential upside from upcoming data releases on Keytruda and other pipeline assets.
Background
Guggenheim updated its estimates and reiterated a Buy rating for Merck before the company's Q3 earnings, citing a $400 M R&D charge and recent trial data.
Ticker impact
Guggenheim maintained a Buy rating and cut Q3 sales and EPS estimates for Merck ahead of its upcoming earnings release.
likely downside as the market prices in the reduced guidance.
The rating and forecast cut are new analyst actions that can move the stock before earnings.
Market effects
May weigh on the broader pharma sector as analysts reassess Q3 outlooks.
U.S. market focus on upcoming earnings season.
Limited to investors tracking large‑cap biotech/ pharma stocks.
Counterpoint
Some investors may view the Buy rating as a buying opportunity despite the forecast cut.
Key entities
- companyMerck & Co.
Pharmaceutical giant MRK.
- analystGuggenheim
Equity research firm issuing the rating and forecasts.
